A Markov Model-Based Cost-Effectiveness Analysis of Interventions for Non-Alcoholic Fatty Liver Disease and Steatohepatitis

<a href="https://embed.stanford.edu/iframe/?url=https%3A%2F%2Fpurl.stanford.edu%2Fnr644yx3574" class="su-underline">Show Content</a>

Abstract/Contents

Abstract: Non-alcoholic fatty liver disease (NAFLD) and its more aggressive form, non-alcoholic steatohepatitis (NASH), are the most prevalent liver diseases in the U.S. and throughout the world, and that prevalence is increasing. The current standard of care for these diseases is weight loss through diet and exercise with counseling support. No medications for NAFLD/NASH have been approved by the FDA. Using a Markov model with parameters from the literature, we compared the cost-effectiveness of no treatment, diet/exercise, bariatric surgery, and semaglutide, a possible treatment for NAFLD/NASH currently undergoing clinical trials. Diet/exercise and bariatric surgery are cost-effective alternatives to no treatment, but semaglutide is not cost-effective compared to other treatment options due to its high cost. Conditional policies where patients switch to bariatric surgery after one year of diet/exercise if they lose < 5%, < 7%, or < 10% of their weight are also cost-effective. Therefore, diet/exercise should remain the standard of care for most NAFLD/NASH patients even if semaglutide becomes FDA- approved. Bariatric surgery is a cost-effective alternative for NAFLD/NASH patients with a qualifying BMI.

Author	Collins, Andrea
Thesis advisor	Valiant, Gregory
Thesis advisor	Shachter, Ross
Degree granting institution	Stanford University
Department	Department of Computer Science

DOI	https://doi.org/10.25740/nr644yx3574
Location	https://purl.stanford.edu/nr644yx3574

Use and reproduction: User agrees that, where applicable, content will not be used to identify or to otherwise infringe the privacy or confidentiality rights of individuals. Content distributed via the Stanford Digital Repository may be subject to additional license and use restrictions applied by the depositor.
License: This work is licensed under a Creative Commons Attribution Non Commercial 4.0 International license (CC BY-NC).

Preferred citation: Collins, A. (2022). A Markov Model-Based Cost-Effectiveness Analysis of Interventions for Non-Alcoholic Fatty Liver Disease and Steatohepatitis. Stanford Digital Repository. Available at https://purl.stanford.edu/nr644yx3574

Undergraduate Theses, School of Engineering

Loading usage metrics...